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Abstract
Context Glucocorticoid receptor (GR) polymorphisms
modulate glucocorticoid (GC) sensitivity and are associ-
ated with altered metabolic profiles.
Objective To evaluate the presence of GR polymor-
phisms (BclI (rs41423247), N363S (rs56149945), ER22/
23EK (rs6189/rs6190), and 9b (rs6198) and investigate
their associations with metabolic alterations in patients in
long-term remission of Cushing’s syndrome (CS).
Design and setting Cross-sectional case–control study.
Patients and methods Sixty patients in long-term remis-
sion of CS were genotyped. Associations between GR
polymorphisms and multiple vascular, body composition
and metabolic parameters were investigated.
Main outcome measures Allelic frequencies of the poly-
morphisms and their associations with several car-
diometabolic risk factors.
Results This study shows that carriers of the 9b poly-
morphism have a higher systolic blood pressure and lower
resistin levels. The GC sensitizing BclI polymorphism is
associated with an adverse cardiometabolic risk factor
profile: higher fat percentages of extremities and legs,
higher serum leptin and E-selectin levels, and higher intima
media thickness in carriers versus non-carriers.
Conclusions The 9b and BclI polymorphisms of the GR
adversely affect the cardiometabolic profile in patients who
are in remission after the treatment of CS. This suggests
that genetically altered GC sensitivity modulates the long-
term adverse cardiometabolic effects resulting from (en-
dogenous) hypercortisolism.
Keywords Cushing’s syndrome  Long-term remission 
Glucocorticoid receptor polymorphisms  Genetic
predisposition  Metabolic profile
Introduction
Cushing’s syndrome (CS) is a disorder resulting from
chronic exposure to increased levels of glucocorticoids
(GC), frequently caused by an ACTH-producing pituitary
adenoma [Cushing’s disease (CD)] or by primary adrenal
overproduction of cortisol [adrenal CS (ACS)] [1]. CS is
associated with body composition changes, cardiometabolic
abnormalities such as type 2 diabetes mellitus (T2DM),
hypertension and dyslipidemia, and ultimately cardiovas-
cular disease [2]. We [3] and others [4, 5] have shown that
many adverse metabolic and cardiovascular characteristics,
and body compositional changes persist after treatment,
even after long-term remission. Although these adverse
metabolic and cardiovascular characteristics are common in
these patients, their incidence and severity vary among
patients. This variation seems not to be explained by dif-
ferences in cortisol excess or disease duration alone.
Therefore, a variable sensitivity to GC possibly plays a role
in modulating the effect of cortisol excess [6].
Several investigations in healthy subjects have shown
that GR polymorphisms are associated with altered GC
sensitivity and alterations in metabolic profiles and body
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composition. The BclI and N363S polymorphisms of the
GR gene have been associated with enhanced sensitivity to
GC, increased abdominal obesity, an adverse lipid profile,
and hyperinsulinemia [7–10]. In contrast, the ER22/23EK
GR polymorphism has been associated with GC resistance
and a favorable metabolic profile and body composition
[11, 12]. The 9b polymorphism is associated with increased
expression and stabilization of the dominant-negative
splice variant GR-b. Enhanced GR-b expression results in
greater inhibition of GR-a transcriptional activity, and as
GR-a is the functional GR isoform, in relative GC resis-
tance [13–15]. This polymorphism is associated with
increased serum levels of inflammatory parameters and
cardiovascular disease despite a more favorable lipid pro-
file in men and body composition in women [16, 17].
The functional role of GR polymorphisms has been
extensively studied in the general healthy population. In
contrast, only a small number of studies have been per-
formed on the functional role of GR polymorphisms in
active CS and CS in remission. These few studies have
found an association of the 9b polymorphism with the risk
of developing diabetes mellitus [18] and of the BclI poly-
morphism with increased skeletal GC sensitivity and worse
cognitive performance [19, 20].
We hypothesize that differences between patients in the
severity of the adverse metabolic and vascular profile after
cure of CS are related to differences in GC sensitivity due
to GC receptor polymorphisms. Therefore, we investigated
the associations of these genetic variants with the presence/
persistence of the adverse metabolic and vascular profile
and body composition after long-term remission of CS.
Subjects and methods
Sixty adult ([18-year old) patients in long-term remission
([4 years) of CS were recruited from the outpatient clinic
of the department of internal medicine. Remission was
defined as suppression of plasma cortisol to B50 nmol/L
after 1 mg dexamethasone overnight [21] or, if a patient
had received radiotherapy of the pituitary gland, a 24-h
urinary-free cortisol excretion of\240 nmol/24 h for men
or\150 nmol/24 h for women (upper levels of normal-free
cortisol excretion). Clinical history was collected and a
physical examination, biochemical and hormonal evalua-
tion, dual-energy X-ray absorptiometry scanning (DXA),
and non-invasive vascular function measurements were
performed in all subjects. All subjects were genotyped for
the presence of four GR polymorphisms; BclI, N363S,
ER22/23EK, and 9b.
Patients with untreated hormonal deficiencies, or hor-
monal deficiencies that had not been treated adequately in
the last 4 years according to international standards, were
excluded. Furthermore, patients with active malignancy or
systemic therapy for malignancy in the past, auto-inflam-
matory diseases, and psychiatric pathology were excluded.
Hypothyroidism was defined as free thyroxine (fT4) plasma
concentrations \8 pmol/l (reference range 8–22 pmol/l).
Testosterone deficiency in men was defined as early
morning testosterone levels \11 nmol/l (reference range
11–45 nmol/l). In women, estrogen deficiency was defined
as secondary hypogonadotropic hypogonadism or a post-
menopausal state without the use of chronic estrogen
substitution therapy. Growth hormone (GH) deficiency was
defined as a maximal GH response of\15.3 mU/l during
an insulin tolerance test (ITT), or as a maximal GH
response of \12.3 mU/l during an arginine/GHRH test
[22]. Glucocorticoid deficiency was defined as a maximal
cortisol response \550 nmol/l during an ITT [23]. All
patients underwent a new 1 mg dexamethasone suppres-
sion test (or a 24-h urinary-free cortisol measurement in
case of pituitary RT) before entering the study to confirm
remission. All subjects were of Caucasian (Dutch) origin.
Clinical history
Clinical history included the etiology of CS, treatment
strategies (surgery, radiotherapy, medication), treatment
for coexisting hormonal deficiencies, co-morbidities, and
smoking habits.
Physical examination
Anthropometric measurements including weight and
height, supine systolic, and diastolic blood pressure [av-
erage of 10 measurements, every 3 min with an oscillo-
metric sphygmomanometer (Criticon model 1846; Criticon
Inc., Tampa, FL)] measured at 09:00AM.
Biochemical evaluation
Biochemical evaluation included plasma level measure-
ments of fasting glucose, glycated hemoglobin (HbA1c),
total cholesterol, triglycerides, high-density lipoprotein
(HDL), low-density lipoprotein (LDL), and insulin. Insulin
sensitivity was assessed by homeostasis model assessment
(HOMA) [24]. Furthermore, serum adipokines adiponectin,
leptin, and resistin were measured. In addition, a number of
markers of vascular health were measured in serum; sol-
uble vascular cell adhesion molecule-1 (VCAM-1), soluble
intercellular adhesion molecule-1 (ICAM-1), plasminogen
activator inhibitor-1 (PAI-1), and soluble E-selectin.
Increased levels of these parameters are indicators of
endothelial dysfunction and worse vascular health.
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Vascular evaluation
Carotid intima media thickness (IMT) was determined
using an AU5 ultrasound machine (Esaote Biomedical)
with a 7.5 MHz linear array transducer. Measurement of
IMT was performed off-line by the sonographer at the time
of the examination, using semi-automatic edge-detection
software (M’Ath Std version 2.0, Metris). IMT was
defined as the mean IMT of the four measured segments of
the common carotid artery: far wall left, near wall left, far
wall right, and near wall right.
Body composition
Total body DXA was performed using a Hologic QDR
4500 densitometer (Hologic, Bedford, MA). Standard
procedures supplied by the manufacturer for scanning and
analyses (using Hologic software version 12.1) were fol-
lowed. Calibration procedures were performed every day
using the appropriate phantoms provided by the manufac-
turer. Total body fat mass was determined and fat per-
centage was calculated as the total body fat mass in percent
of body weight. Furthermore, trunk-, leg-, and extremities
fat percentages were determined in order to discriminate
between different body regions. Different regions were
determined by manually placing regions of interest as
defined by the manufacturers software manual. The trunk
fat depot is defined as the region between two horizontal
lines placed on the lower border of the head and the upper
border of the iliac crest, and two vertical lines placed
against the outer margins of the chest. These lines exclude
the arms from the trunk. The leg fat depot is defined by two
vertical lines placed against the outer margins op both legs.
The pelvis is excluded from the legs by a line through the
femoral neck. Leg fat percentage is depicted as the average
of both legs. Extremity fat percentage is depicted as the
average of both arms and both legs.
Laboratory measurements
Serum concentrations of leptin, resistin, PAI-1, sICAM-1,
and soluble E-selectin were measured by Multiplex Fluo-
rescent Bead Immunoassays (xMAP technology, Milli-
pore, Billerica, MA) and a Bio-plex microbead analyzer
(Luminex, Austin, TX) according to the manufacturers
protocol. Serum concentrations of adiponectin and sVCAM-
1 were determined by enzyme-linked immunosorbent assays
(R&D Systems, Minneapolis, MN). Fasting plasma glucose,
HbA1c, insulin and total serum cholesterol, triglycerides,
LDL-cholesterol, and HDL-cholesterol were measured by
standard procedures. According to the manufacturer’s
information, intra-assay precision coefficients of variation
for all laboratory measurements were equal or below 5 %.
Genetic analyses
DNA was isolated from whole blood using the Gentra
Puregene isolation kit (Qiagen, Valencia, CA, USA),
according to the manufacturers protocol. Genotyping for the
four selected genetic variants of the glucocorticoid receptor
(GR) gene (official gene name NR3C1) was performed as
follows. The presence of the 9b (rs6198) and N363S
(rs56149945) genetic variants was assessed by applying the
predesigned TaqMan SNP assays C_8951023_10 and
C_26841917_40, respectively, on a 7300 ABI Real-Time
polymerase chain reaction (PCR) system (all from Life
Technologies, Applied Biosystems, Foster City, CA).
For the detection of the GR ER22/23EK (rs6189/rs6190),
genetic variant conventional PCR and Sanger sequencing
analysis were performed with forward primer 50-CTG-CCT-
CTT-ACT-AAT-CGG-ATC-A-30 and reverse primer 50-
AGA-GTG-AAA-CTG-CTT-TGG-ACA-G-30. To deter-
mine the GR BclI genotype (rs41423247), DNA was ampli-
fied with forward primer 50-AAG-CAA-TGC-AGT-GAA-
CAG-TGT-AC-30 and reverse primer 50-AAC-AAT-TTT-
GGC-CAT-CAG-TTA-TC-30. Also these PCR products were
subjected to Sanger sequencing analysis.
Statistical analyses
Data are expressed as mean ± 95 % confidence intervals
unless stated otherwise. Data distributions were analyzed
using the Kolmogorov–Smirnov test, and logarithmic
transformation was performed before statistical testing
when appropriate. Based on data distribution, comparison
of continuous variables was performed using Student’s
t test or Mann–Whitney rank sum test. The associations
between genotypes and outcome measurements were
evaluated using analysis of covariance (ANCOVA) with
genotypes as a factor and age, gender, and BMI as
covariates. Categorical variables were analyzed using the
v2 test followed by Fisher’s exact test if appropriate.
Hardy–Weinberg equilibrium for all polymorphisms was
determined using a v2 test. Significance was set at a
P value of\0.05. Statistical analysis was performed using
SPSS Software version 20.0 (SPSS, Inc., Chicago, IL).
Results
Forty-eight (80 %) subjects were female. Mean (SD) age
was 50.7 (12.4) years with a mean (SD) BMI of 26.9 (5.3)
kg/m2. Mean (SD) duration of remission was 13.8 (8.5)
years. Nineteen (31.7 %) subjects were treated for hyper-
tension, 4 (6.7 %) were treated for diabetes mellitus, and
12 (20.0 %) were treated for hypercholesterolemia. Com-
plete subject characteristics of all subjects are depicted in
Endocrine (2016) 53:63–70 65
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Table 1. Allelic frequencies of the four polymorphisms are
depicted in Table 2. All polymorphisms were in Hardy–
Weinberg equilibrium. Because of low allele frequencies,
the N363S and ER22/23EK polymorphisms were not
included in the association analysis. The minor allele of the
9b polymorphism showed a statistically significant asso-
ciation with higher systolic blood pressure (P = 0.007) and
lower resistin levels (P = 0.027) in carriers (Table 3;
Fig. 1a). No associations were detected for the other
measured parameters. The minor allele of the BclI geno-
type showed statistically significant associations with
higher mean IMT (P = 0.048), higher extremities fat per-
centage (P = 0.007), higher leg fat percentage (P =
0.029), higher leptin level (P = 0.038), and higher soluble
E-selectin level (P = 0.037) in carriers (Table 3; Fig. 1b).
No associations with the other measures were detected in
our CS patients (data not shown).
Discussion
This study investigated the prevalence of GR polymor-
phisms in patients in long-term remission of CS and the
associations of these polymorphisms with metabolic, vas-
cular, and body compositional characteristics. In this study,
we found that carriers of the 9b polymorphism have a
higher systolic blood pressure and lower resistin levels and
that the GC sensitizing BclI polymorphism is associated
with a number of metabolic and vascular adverse effects:
higher fat percentages of extremities and legs, higher serum
leptin, E-selectin levels, and higher intima media thickness
in carriers versus non-carriers.
It has been shown that in patients in long-term remission
of CS, cardiovascular and metabolic risk remain increased
[3, 5]. In the general population, it has been demonstrated
that cardiovascular and metabolic risk and body composi-
tion are affected by lifelong overactivation or relative
inactivation of GC signaling due to GR polymorphisms
[25]. Our observation that altered glucocorticoid sensitivity
due to GR polymorphisms modulates cardiometabolic risk
factors in cured CS patients is in line with these well-
known findings in the general population.
Remitted CS patients carrying the minor allele of the 9b
polymorphism had a higher systolic blood pressure, which
is concordant with previous findings of an increase in
Table 1 Subject characteristics
(n = 60)
Gender (n): male/female 12/48
Age in years: mean (SD) 50.7 (12.4)
Duration of remission: mean (SD) 13.8 (8.5)
BMI in kg/m2 : mean (SD) 26.9 (5.3)
Waist circumference in cm: mean (SD) 91.8 (14.7)
Smoking (n): yes/no 14/45
Treatment modalities: n (%)
Unilateral adrenalectomy 20 (33.3)
Bilateral adrenalectomy 12 (20.0)
Pituitary surgery 38 (63.3)
Pituitary radiotherapy 13 (21.7)
Hormonal deficiencies: n (%)
Glucocorticoid deficiency* 22 (36.7)
Growth hormone deficiency* 15 (25.0)
Thyroid hormone deficiency* 26 (43.3)
Testosterone deficiency* 6 (10.0)
Mineralocorticoid deficiency* 11 (18.3)
Estrogen deficiency 26 (54.2)
Cardiometabolic co-morbidities: n (%)
Hypertension** 19 (31.7)
Diabetes mellitus** 4 (6.7)
Hypercholesterolemia** 12 (20.0)
Cushing type: n (%)
Pituitary 40 (66.7)
Adrenal 20 (33.3)
BMI body mass index, CS Cushing’s syndrome
* Adequately substituted according to international standards
** Actively treated for this co-morbidity
Table 2 Genotype distributions and allele frequencies of the GR
gene polymorphisms in patients cured of Cushing’s syndrome (CS)
CS (n = 60)
BclI
CC 32 (53 %)
CG 20 (33 %)
GG 8 (13 %)
Allele frequency 0.300
9b (A3669G)
AA 40 (67 %)
AG 19 (32 %)
GG 1 (2 %)
Allele frequency 0.175
N363S
AA 55 (92 %)
AG 5 (8 %)
GG 0 (0 %)
Allele frequency 0.042
ER22/23EK
GG 55 (92 %)
GA 5 (8 %)
AA 0 (0 %)
Allele frequency 0.042
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carotid atherosclerosis, and a higher incidence of coronary
heart disease in carriers of this polymorphism [17]. Systolic
hypertension is normally especially seen in the elderly
population due to increased arterial stiffening. Arterial
stiffness is central to the pathogenesis of isolated systolic
hypertension and directly impacts left ventricular afterload,
pressure pulsatility in the arterial tree, and its penetration
into the microvasculature of target organs such as the brain
and kidney. This means that systolic hypertension in
carriers of the polymorphism may lead to increased aging
of the vascular tree, but further studies are needed to elu-
cidate whether the polymorphism increases cardiovascular
risk. Furthermore, an association was found between the 9b
polymorphism and resistin levels, with carriers of the
minor allele of the 9b polymorphism having lower resistin
levels. It can be hypothesized that this is caused by the fact
that subjects with a relative decrease in glucocorticoid
sensitivity have less central adiposity. Central adiposity
Fig. 1 a Associations of the 9b genotype and clinical outcome *P\ 0.05. b Associations of the BclI genotype and clinical outcome *P\ 0.05
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Table 3 Associations between
glucocorticoid receptor
polymorphisms and outcome
measurements
Carrier minor allele Non-carrier minor allele P value
9b
Fasting glucose (mmol/l) 5.1 (4.7-5.4) 5.0 (4.7–5.2) 0.578
HbA1c (mmol/mol) 40.9 (38.4-43.6) 38.4 (36.7–40.1) 0.117
Total cholesterol (mmol/l) 5.3 (5.0–5.7) 5.2 (4.8–5.5) 0.596
Triglycerides (mmol/l) 1.4 (1.2–1.8) 1.5 (1.3–1.7) 0.850
HDL-cholesterol (mmol/l) 1.3 (1.2–1.5) 1.4 (1.3–1.4) 0.919
LDL-cholesterol (mmol/l) 3.2 (2.9–3.6) 3.1 (2.9–3.3) 0.498
Insulin (mE/l) 6.0 (4.6–7.8) 7.2 (6.0–8.7) 0.266
HOMA-IR 1.4 (1.1–1.9) 1.6 (1.3–2.0) 0.574
Mean IMT (mm) 0.73 (0.70–0.77) 0.76 (0.73–0.78) 0.254
Systolic blood pressure (mmHg) 138.7 (131.2–146.5) 126.2 (121.5–131.1) 0.007*
Total body fat (%) 32.6 (30.8–34.3) 34.3 (33.1–35.2) 0.114
Trunk fat (%) 32.3 (30.4–34.3) 33.2 (31.8–34.5) 0.471
Extremities fat (%) 35.8 (34.2–37.5) 38.1 (36.9–39.2) 0.340
Leg fat (%) 34.0 (32.1–36.1) 35.4 (34.0–36.9) 0.271
Leptin (pg/ml) 3374.5 (2289.3–4974.1) 4213.3 (3206.7–5535.9) 0.356
Resistin (pg/ml) 2248.5 (1618.1–3124.4) 3558.2 (2824.3–4482.8) 0.020*
Adiponectin (pg/ml) 706.3 (458.1–1089.0) 1087.9 (802.7–1474.4) 0.108
PAI-1 (pg/ml) 1884.7 (1377.2–2392.3) 2384.8 (2027.4–2742.2) 0.114
VCAM-1 (pg/ml) 666.5 (576.5–770.5) 674.5 609.7–746.2) 0.888
ICAM-1 (pg/ml) 253.4 (177.0–362.9) 304.3 (236.3–391.9) 0.410
E-selectin (pg/ml) 46.2 (37.9–54.5) 42.2 (36.3–48.1) 0.436
BclI
Fasting glucose (mmol/l) 5.2 (4.9–5.5) 4.8 (4.6–5.1) 0.097
HbA1c (mmol/mol) 40.6 (38.5–42.8) 38.1 (36.2–40.0) 0.089
Total cholesterol (mmol/l) 5.2 (4.9–5.6) 5.2 (4.9–5.5) 0.837
Triglycerides (mmol/l) 1.6 (1.4–1.9) 1.3 (1.1–1.6) 0.198
HDL-cholesterol (mmol/l) 1.4 (1.2–1.5) 1.4 (1.3–1.4) 0.969
LDL-cholesterol (mmol/l) 3.1 (2.9–3.4) 3.2 (2.9–3.4) 0.879
Insulin (mE/l) 7.4 (5.9–9.2) 6.3 (5.1–7.8) 0.313
HOMA-IR 1.8 (1.4–2.3) 1.4 (1.1–1.7) 0.125
Mean IMT (mm) 0.77 (0.74–0.80) 0.73 (0.70–0.76) 0.048*
Systolic blood pressure (mmHg) 126.0 (120.2–132.0) 134.0 (128.3–14.-1) 0.060
Total body fat (%) 34.5 (33.0–36.0) 33.1 (31.7–34.4) 0.167
Trunk fat (%) 33.3 (31.7–34.9) 32.5 (31.0–34.1) 0.488
Extremities fat (%) 38.7 (37.3–40.1) 36.1 (34.8–37.4) 0.007*
Leg fat (%) 37.5 (35.8–39.1) 35.0 (33.5–36.5) 0.029*
Leptin (pg/ml) 4999.0 (3644.6–6856.8) 3155.8 (2869.8–3470.3) 0.038*
Resistin (pg/ml) 3630.0 (2738.1–4812.6) 2625.4 (2016.3–3418.7) 0.099
Adiponectin (pg/ml) 1166.8 (811.6–1677.4) 781.3 (556.1–1097.7) 0.112
PAI-1 (pg/ml) 2301.6 (1866.2–2737.1) 2145.0 (1737.8–2552.2) 0.602
VCAM-1 (pg/ml) 726.3 (645.5–817.3) 627.7 (562.3–700.6) 0.075
ICAM-1 (pg/ml) 282.3 (208.5–382.2) 289.5 (218.1–384.1) 0.904
E-selectin (ng/ml) 45.2 (38.8–52.7) 36.1 (31.3–41.7) 0.037*
Data are expressed as mean and 95 % confidence intervals
All data are adjusted for age, gender, and BMI
IMT intima media thickness, HbA1c glycated hemoglobin, HDL high-density lipoprotein, LDL low-density
lipoprotein, HOMA-IR homeostatic model assessment-insulin resistance, PAI plasminogen activator inhi-
bitor, VCAM vascular cell adhesion molecule, ICAM intracellular adhesion molecule
* P ANCOVA was used to assess the statistical differences between genotype groups, P\ 0.05 (bold)
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causes local ischemia of the adipose tissue which leads to
infiltration of M1-macrophages, which are the main pro-
ducers of resistin. This hypothesis is, however, speculative
and not supported by the data, since no association between
truncal fat and the 9b polymorphism was observed.
The minor allele of the BclI polymorphism was asso-
ciated with an increased fat percentage of the extremities
and legs in the remitted CS patients. These body areas only
contain subcutaneous adipose tissue. As leptin is prefer-
entially produced in subcutaneous adipose tissue (SAT),
carriers also had higher leptin levels [26]. High leptin
levels have been widely recognized as an independent
cardiovascular risk factor associated with insulin resis-
tance. It also has a pathogenic role in atherothrombosis and
endothelial dysfunction. Furthermore, a higher level of
E-selectin was found in carriers of the minor allele of the
BclI polymorphism. This may reflect increased endothelial
activation and progressing atherosclerosis in the BclI car-
riers. This is supported by our observation that the IMT is
higher in BclI carriers.
In women with CS in remission, the BclI polymorphism
was previously shown to be associated with altered GC
sensitivity as the polymorphism was associated with
reduced total and femoral neck bone mineral density [27].
Furthermore, in patients in remission of CS, the BclI
polymorphism was also independently associated with
increased fatigue and worse performance on cognitive
testing [20]. The findings in literature combined with the
findings in the current study suggest that hypercortisolism
in patients carrying the BclI polymorphism may have more
pronounced effects on patient wellbeing in the long term.
This study has some limitations. Because of the low
incidence of CS, only a relatively small cohort could be
studied. This could influence genetic associations and that
is why only polymorphisms with a relatively high fre-
quency were included in the association analysis. In genetic
association studies, inhomogeneity of study population
with regard to ethnicity, gender, age, and environmental
factors is a frequent limiting factor. This study included
Caucasians only and associations were corrected for gender
and age. Duration of hypercortisolism likely represents
another factor in long-term cardiometabolic effects in CS
patients, which, however, is rather difficult to estimate
since diagnosis of CS is generally delayed. Furthermore, it
was decided not to correct for multiple testing because of
the hypothesis-driven nature of this study. Indeed, from a
biological perspective our findings are in line with the
expected corticosteroid effects, suggesting that SNPs of the
GR gene leading to either hypo- or hypersensitivity to GC,
indeed modulate long-term cardiometabolic outcome after
treatment of CS. However, because of the limited sample
size and, hence, limited statistical power, we cannot
exclude that some of the significant differences between
carriers and non-carriers may be a finding by chance, i.e., a
type-1 error.
In conclusion, this study is one of the first to suggest that
glucocorticoid receptor polymorphisms modulate car-
diometabolic risk factors in patients in long-term remission
of CS [27]. In the context of personalized healthcare, this
may implicate that, after treatment of CS, carriers of these
polymorphisms are candidates for a more stringent follow-
up regarding cardiovascular and metabolic health as our
findings suggest that GR polymorphisms may play a role in
susceptibility to cardiovascular disease in CS patients.
Furthermore, patients who treated with glucocorticoids for
other diseases and even healthy subjects, carrying these
polymorphisms, are candidates for a more stringent follow-
up regarding cardiovascular and metabolic health, and the
development of metabolic syndrome as was recently
debated in literature [28]. However, the results of this study
need to be interpreted with caution, and further research
into these findings in larger CS populations is needed to
replicate these findings. In addition, future studies should
delineate to what extent the observed associations also
apply to prolonged episodes of exposure to physiologically
elevated cortisol levels (e.g., severe stress) or exogenous
glucocorticoids.
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